CD19 and diffuse large B-cell lymphoma: • R/R B-NHL(n=37)• Median age (range): 64 (26-79)• min. of ≥ 2 PLoT• Median (range) number of prior therapies: 4 (2-10)• Stage III/IV disease: 14 (63.6%)• R/R DLBCL (n=17)• No prior CD19-CAR-T (for dose extension phase)• Prior alloHSCT permitted